14,815 results match your criteria treatment infliximab

The effects of infliximab in treating idiopathic inflammatory myopathies: A review article.

Dermatol Ther 2021 May 14:e14976. Epub 2021 May 14.

Department of Rheumatology, China-Japan Friendship Hospital, Yinghua East Road, Chaoyang District, 100029, Beijing, China.

Anti-TNF treatment may be useful for patients with idiopathic inflammatory myopathies (IIMs). The purpose of this study is to assess the efficacy of infliximab (IFX) in the management of IIMs. Two databases (ie, PubMed and China National Knowledge Infrastructure) were searched up to Nov 2020 for studies investigating skin lesions and muscular weakness in patients with IIMs treated with IFX. Read More

View Article and Full-Text PDF

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.

Front Pharmacol 2021 14;12:654985. Epub 2021 Apr 14.

Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China.

The primary non-response (PNR) rate of infliximab (IFX) varies from 20 to 46% for the treatment of Crohn's disease (CD). Detected PNR reduces the improper use of specific treatments. To date, there is hardly any knowledge regarding early markers of PNR. Read More

View Article and Full-Text PDF

Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model.

Inflammopharmacology 2021 May 12. Epub 2021 May 12.

Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus, 54124, Thessaloniki, Greece.

Reduced Bone Mineral Density (BMD) and tendon abnormalities, such as tenosynovitis and enthesitis, are prevalent comorbidities in patients with rheumatoid arthritis (RA). The aim of the present study was to investigate the effect of chronic treatment with infliximab on BMD and tendon inflammation in an animal model of inflammatory arthritis. Collagen-Induced Arthritis (CIA) was induced in rats, followed by long-term intraperitoneal administration of infliximab. Read More

View Article and Full-Text PDF

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease.

Pediatr Qual Saf 2021 May-Jun;6(3):e400. Epub 2021 May 5.

Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Achieving and maintaining target serum trough infliximab levels improves outcomes in children and young adults with inflammatory bowel disease. Our goal was to improve adherence to an infliximab therapy guideline. The primary aim was to increase the percentage of patients with infliximab levels ≥5 μg/mL and results checked in the last 12 months from 73% to ≥80% from July 2017 to January 2018. Read More

View Article and Full-Text PDF

Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis.

Arthritis Care Res (Hoboken) 2021 May 10. Epub 2021 May 10.

Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.

Objective: To compare the risk of serious infections requiring hospitalization in patients with psoriasis (PsO) or psoriatic arthritis (PsA) initiating ustekinumab versus other biologics or apremilast.

Methods: In this multi-database cohort study, we identified patients with PsO/PsA who initiated adalimumab, apremilast, certolizumab, etanercept, golimumab, ixekizumab, secukinumab, or ustekinumab between 2009 and 2018. The primary outcome was hospitalized serious infections including bacterial, viral, or opportunistic infections. Read More

View Article and Full-Text PDF

Sarcoidosis presenting with glazy mucoid sputum and dyspnea: a case report.

J Med Case Rep 2021 May 11;15(1):232. Epub 2021 May 11.

Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, AA11, PO Box 30001, 9700 RB, Groningen, The Netherlands.

Background: Patients with pulmonary sarcoidosis commonly present with a dry cough; a productive cough suggests a complicating airway infection or an alternative diagnosis such as tuberculosis or bronchiectasis.

Case Presentation: A 36-year-old European (Frisian) woman recently diagnosed with pulmonary sarcoidosis presented with debilitating exertional dyspnea and cough productive of glazy mucoid sputum. Several different attempts including video-assisted thoracoscopic biopsies failed to reach a second or alternative diagnosis including an infectious, autoimmune or collagen-vascular condition. Read More

View Article and Full-Text PDF

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report.

World J Clin Cases 2021 May;9(13):3219-3226

Department of Internal Medicine, São Paulo State University (Unesp), Medical School, Botucatu 18618687, São Paulo, Brazil.

Background: Acute severe ulcerative colitis (ASUC) is a complication of ulcerative colitis associated with high levels of circulating tumor necrosis factor alpha, due to the intense inflammation and faster stool clearance of anti-tumor necrosis factor drugs. Dose-intensified infliximab treatment can be beneficial and is associated with lower rates of colectomy. The aim of the study was to present a case of a patient with ASUC and megacolon, treated with hydrocortisone and accelerated scheme of infliximab that was monitored by drug trough level. Read More

View Article and Full-Text PDF

Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.

Int Immunopharmacol 2021 May 6;96:107722. Epub 2021 May 6.

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200072, China; Department of Dermatology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China. Electronic address:

Background: Psoriasis is a T cell-mediated autoimmune skin disease. Accumulating evidence has demonstrated that co-inhibitory receptors (CIRs) play a vital role in regulating T cell-mediated immune response, especially in neoplasm and autoimmunity. However, the immuno-function of CIRs in the development of psoriasis remains unclear. Read More

View Article and Full-Text PDF

Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis.

Transl Res 2021 May 6. Epub 2021 May 6.

Scipher Medicine Corporation, Waltham, MA. Electronic address:

This cross-cohort study aimed to 1) determine a network-based molecular signature that predicts the likelihood of inadequate response to the tumor necrosis factor-ɑ inhibitor (TNFi) therapy, infliximab, in ulcerative colitis (UC) patients and 2) address biomarker irreproducibility across different cohort studies. Whole-transcriptome microarray data were derived from biopsies of affected colon tissue from two cohorts of infliximab-treated UC patients (training N=24 and validation N=22). Response was defined as endoscopic and histologic healing at 4-6 weeks and 8 weeks, respectively. Read More

View Article and Full-Text PDF

Efficacy of infliximab in treatment-naïve patients with stricturing small bowel Crohn's disease.

Scand J Gastroenterol 2021 May 7:1-8. Epub 2021 May 7.

Department of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.

Objectives: The efficacy of infliximab in treatment-naïve patients with stricturing small bowel Crohn's disease (CD) has not been well studied. We aimed to evaluate the efficacy of infliximab in these patients.

Materials And Methods: This was a retrospective study of all consecutive treatment-naïve patients with newly diagnosed CD with small bowel stricture who started regular infliximab therapy in Nanfang Hospital between January 2015 and December 2019. Read More

View Article and Full-Text PDF

Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis.

BMJ Case Rep 2021 May 6;14(5). Epub 2021 May 6.

Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan.

Although prednisolone, granulocyte/monocyte apheresis, calcineurin inhibitor and anti-tumour necrosis factor (TNF) therapy are generally used, no treatment strategy for inflammatory bowel disease complicated with pyoderma gangrenosum (PG) has been established yet. Herein, we present the case of a 29-year-old man with ulcerative colitis (UC) complicated with primary sclerosing cholangitis. When UC relapsed and PG developed, prednisolone and granulocyte/monocyte apheresis were used; however, their therapeutic effects were deemed insufficient. Read More

View Article and Full-Text PDF

Treatment of Generalized Pustular Psoriasis of Pregnancy With Infliximab.

Cutis 2021 Mar;107(3):E2-E5

Dr. Beksac is from the Department of Dermatology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey. Dr. Adisen is from and Dr. Gurer was from the Department of Dermatology, Gazi University Faculty of Medicine, Ankara, Turkey.

Generalized pustular psoriasis of pregnancy (GPPP) is a rare and severe condition that may impair the health of the mother and fetus. Effective treatment is essential, as treatment options for GPPP are limited due to concerns about unfavorable pregnancy outcomes. We report the case of a 22-year-old woman with GPPP that was unresponsive to systemic corticosteroids. Read More

View Article and Full-Text PDF

Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin.

Biologics 2021 27;15:107-113. Epub 2021 Apr 27.

Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.

The global pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging. Various cutaneous manifestations have been observed in patients with SARS-CoV-2 infection, yet exacerbations of psoriasis have been reported sporadically. Acrodermatitis continua of Hallopeau (ACH) is an uncommon, sterile pustular dermatosis involving one or more digits. Read More

View Article and Full-Text PDF

Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study.

Ann Gastroenterol 2021 27;34(3):370-377. Epub 2021 Jan 27.

IBD Referral Center, Department of Gastroenterology, AOU Careggi Hospital, Florence, Italy (Marco Le Grazie, Siro Bagnoli, Gabriele Dragoni, Tommaso Innocenti, Stefano Milani, Andrea Galli, Monica Milla).

Background: Acute severe ulcerative colitis (ASUC) is a potentially life-threatening disease, and the best option in cases of steroid-refractory disease is still debated. We compared the early- and long-term efficacy and safety of the 2 available "rescue therapies", infliximab (IFX) and cyclosporine (CYS), in this setting.

Methods: We retrospectively evaluated patients admitted for ASUC and treated with "rescue therapy". Read More

View Article and Full-Text PDF
January 2021

Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test.

Pathogens 2021 Apr 29;10(5). Epub 2021 Apr 29.

IBD Unit, Department of Gastroenterology, Azienda Sanitaria Friuli Occidentale, Pordenone Hospital, 33170 Pordenone, Italy.

Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a case of extrapulmonary TB in a patient with ulcerative colitis who was treated with Infliximab after a negative Quantiferon Test. Read More

View Article and Full-Text PDF

CNS demyelination with TNFα inhibitor exposure: A retrospective cohort study.

J Neuroimmunol 2021 Apr 26;356:577587. Epub 2021 Apr 26.

Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. Electronic address:

Objective: To study long-term outcomes in patients with CNS demyelinating events exposed to TNFa-inhibitors (TNFai), including subsequent clinical relapse, MRI lesions, and use of disease modifying therapy (DMT) for MS.

Methods: Adult patients evaluated for a CNS demyelinating disease during TNFai use were identified at Mass General Brigham [01/1998-08/2020] and analyzed in clinically-relevant subgroups. Inclusion criteria required a first neurological event while taking a TNFai, MRI lesions consistent with demyelination, and the absence of a more probable alternative diagnosis. Read More

View Article and Full-Text PDF

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

JAMA 2021 05;325(17):1744-1754

Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.

Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab and other biological drugs. However, whether proactive TDM improves clinical outcomes when implemented at the time of drug initiation, compared with standard therapy, remains unclear.

Objective: To assess whether TDM during initiation of infliximab therapy improves treatment efficacy compared with standard infliximab therapy without TDM. Read More

View Article and Full-Text PDF

Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease.

Front Pharmacol 2021 14;12:655865. Epub 2021 Apr 14.

Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.

Crohn disease (CD) is a chronic inflammatory disease that affects quality of life. There are several drugs available for the treatment of CD, but their relative efficacy is unknown due to a lack of high-quality head-to-head randomized controlled trials. To perform a mixed comparison of the efficacy and safety of biosimilars, biologics and JAK1 inhibitors for CD. Read More

View Article and Full-Text PDF

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-Analysis of 1317 Patients From 14 Studies.

Clin Gastroenterol Hepatol 2021 Apr 29. Epub 2021 Apr 29.

Department of Gastroenterology and Hepatology. Electronic address:

Background & Aims: Tools for stratification of relapse risk of Crohn's disease (CD) after anti-tumor necrosis factor (TNF) therapy cessation are needed. We aimed to validate a previously developed prediction model from the diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressants (STORI) trial, and to develop an updated model.

Methods: Cohort studies were selected that reported on anti-TNF cessation in 30 or more CD patients in remission. Read More

View Article and Full-Text PDF

Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.

Pediatr Rheumatol Online J 2021 May 1;19(1):62. Epub 2021 May 1.

Department of Pediatrics, Duke University Hospital, Durham, NC, USA.

Background: Inadequate systemic exposure to infliximab (IFX) is associated with treatment failure. This work evaluated factors associated with reduced IFX exposure in children with autoimmune disorders requiring IFX therapy.

Methods: In this single-center cross-sectional prospective study IFX trough concentrations and anti-drug antibodies (ADAs) were measured in serum from children diagnosed with inflammatory bowel disease (IBD) (n = 73), juvenile idiopathic arthritis (JIA) (n = 16), or uveitis (n = 8) receiving maintenance IFX infusions at an outpatient infusion clinic in a tertiary academic pediatric hospital. Read More

View Article and Full-Text PDF

Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.

Pediatr Rheumatol Online J 2021 May 1;19(1):63. Epub 2021 May 1.

Presbyterian Healthcare Services, New Mexico, Albuquerque, USA.

Background: Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with less than half of exposures progressing to a symptomatic state that primarily consists of pulmonary manifestations. Disseminated coccidioidomycosis is exceedingly rare, occurring in fewer than 1 % of symptomatic infections. Read More

View Article and Full-Text PDF

Implications of COVID-19 infection on patients with uveitis under biologic treatment.

Br J Ophthalmol 2021 Apr 30. Epub 2021 Apr 30.

Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Background/aims: To investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.

Methods: In this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020.

Results: A total of 59 patients were identified. Read More

View Article and Full-Text PDF

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.

Am J Gastroenterol 2021 May;116(5):1007-1014

Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Introduction: There are only limited data regarding the role of therapeutic drug monitoring in fistulizing Crohn's disease (CD). We investigated the association between both induction and maintenance serum infliximab concentrations and favorable therapeutic outcomes in patients with fistulizing CD.

Methods: This was a post hoc analysis of the ACCENT-II trial evaluating patients with fistulizing CD receiving induction (n = 282) and maintenance infliximab therapy (n = 139). Read More

View Article and Full-Text PDF

Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single Center study.

J Dermatolog Treat 2021 Apr 30:1-9. Epub 2021 Apr 30.

Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.

Biosimilar anti-TNF-alpha drugs are widely used in the treatment of psoriasis, but only few studies reported the long term experience of the various biosimilar agents in the real world practice.A monocentric retrospective observational study was performed to assess the long term efficacy, tolerability and safety of biosimilars adalimumab (bADA), biosimilar etanercept (bETN) and biosimilar infliximab (bIFX) in psoriasis patients.A total of 73 patients (19 patient treated with bADA, 37 with bETN and 17 with bIFX) were enrolled and observed up to 48 months of follow-up. Read More

View Article and Full-Text PDF

Unexpected condition in a rare disease: encephalopathy in early-onset sarcoidosis.

Turk J Pediatr 2021 ;63(2):323-328

Department of Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri.

Background: Granulomatous autoinflammatory diseases are monogenic syndromes caused by mutations in the region encoding the nucleotide-binding domain of the nucleotide-binding oligomerization domain-containing 2 gene. Blau syndrome and early-onset sarcoidosis are familial and sporadic forms of the same disease and are very rare. Many organ systems may be involved; however, neurologic involvement is infrequent. Read More

View Article and Full-Text PDF
January 2021